Integrated BioPharma, Inc. (INBP)
OTCMKTS · Delayed Price · Currency is USD
0.1616
-0.01335 (-7.63%)
At close: Sep 18, 2026
Integrated BioPharma Ratios and Metrics
Market cap in millions USD. Fiscal year is July - June.
Millions USD. Fiscal year is Jul - Jun.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 17, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 | Jun '21 Jun 30, 2021 |
| 5 | 11 | 6 | 10 | 15 | 33 | |
Market Cap Growth | -43.63% | 75.42% | -36.28% | -33.74% | -54.33% | 146.41% |
Enterprise Value | 3 | 9 | 6 | 10 | 19 | 41 |
Last Close Price | 0.16 | 0.36 | 0.21 | 0.33 | 0.50 | 1.10 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 17, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 | Jun '21 Jun 30, 2021 |
PE Ratio | - | 13.72 | 56.44 | - | 3.90 | 4.09 |
PS Ratio | 0.10 | 0.20 | 0.13 | 0.20 | 0.27 | 0.52 |
PB Ratio | 0.26 | 0.55 | 0.33 | 0.53 | 0.81 | 2.29 |
P/TBV Ratio | 0.26 | 0.55 | 0.33 | 0.53 | 0.81 | 2.29 |
P/FCF Ratio | 1.77 | 5.92 | 16.21 | 8.89 | 4.15 | 11.90 |
P/OCF Ratio | 1.66 | 5.37 | 6.70 | 8.05 | 3.66 | 10.75 |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 17, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 | Jun '21 Jun 30, 2021 |
EV/Sales Ratio | 0.05 | 0.17 | 0.13 | 0.20 | 0.35 | 0.64 |
EV/EBITDA Ratio | 23.73 | 3.96 | 11.36 | 21.85 | 6.31 | 6.68 |
EV/EBIT Ratio | - | 4.59 | 25.26 | 85.75 | 7.08 | 7.07 |
EV/FCF Ratio | 0.89 | 4.94 | 16.26 | 9.22 | 5.39 | 14.84 |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 17, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 | Jun '21 Jun 30, 2021 |
Debt / Equity Ratio | 0.18 | 0.05 | 0.09 | 0.14 | 0.11 | 0.42 |
Debt / EBITDA Ratio | 31.27 | 0.30 | 1.15 | 1.91 | 0.55 | 0.84 |
Debt / FCF Ratio | 1.18 | 0.54 | 4.61 | 2.39 | 0.57 | 2.18 |
Net Debt / Equity Ratio | -0.13 | -0.13 | 0.01 | 0.07 | 0.09 | 0.40 |
Net Debt / EBITDA Ratio | 2.60 | -1.11 | 0.22 | 2.88 | 0.56 | 0.94 |
Net Debt / FCF Ratio | -0.87 | -1.39 | 0.31 | 1.22 | 0.48 | 2.08 |
Asset Turnover | 1.84 | 2.13 | 1.95 | 2.00 | 2.22 | 2.63 |
Inventory Turnover | 5.06 | 4.74 | 4.32 | 4.37 | 4.37 | 4.96 |
Quick Ratio | 1.72 | 2.13 | 1.04 | 1.21 | 0.99 | 0.66 |
Current Ratio | 3.25 | 4.42 | 2.92 | 3.39 | 3.16 | 1.95 |
Return on Equity (ROE) | -8.40% | 4.08% | 0.59% | -0.18% | 23.33% | 78.55% |
Return on Assets (ROA) | -2.98% | 4.94% | 0.61% | 0.30% | 6.77% | 14.94% |
Return on Invested Capital (ROIC) | -7.93% | 4.27% | 0.53% | -0.20% | 13.61% | 31.50% |
Return on Capital Employed (ROCE) | -5.90% | 9.80% | 1.20% | 0.60% | 13.70% | 35.70% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 17, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 | Jun '21 Jun 30, 2021 |
Earnings Yield | -32.95% | 7.29% | 1.77% | -0.34% | 25.64% | 24.44% |
FCF Yield | 56.56% | 16.90% | 6.17% | 11.25% | 24.08% | 8.40% |
Buyback Yield / Dilution | 1.92% | -0.95% | -3.08% | 7.34% | -0.65% | -3.07% |